BTIG Research upgraded shares of Climb Bio (NASDAQ:CLYM - Free Report) to a strong-buy rating in a research report report published on Thursday morning, MarketBeat.com reports. The firm currently has $7.00 target price on the stock.
Climb Bio Stock Performance
NASDAQ:CLYM traded up $0.01 during mid-day trading on Thursday, reaching $1.19. The company's stock had a trading volume of 33,010 shares, compared to its average volume of 278,861. The company has a market cap of $80.42 million, a PE ratio of -0.56 and a beta of -0.12. The stock's fifty day moving average price is $1.24. Climb Bio has a twelve month low of $1.05 and a twelve month high of $9.58.
Climb Bio (NASDAQ:CLYM - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.16). On average, equities analysts predict that Climb Bio will post -1.57 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. acquired a new position in Climb Bio in the first quarter valued at $147,000. AQR Capital Management LLC purchased a new position in shares of Climb Bio in the 1st quarter worth about $27,000. Allostery Investments LP acquired a new position in shares of Climb Bio in the 1st quarter valued at about $299,000. ADAR1 Capital Management LLC acquired a new position in shares of Climb Bio in the 1st quarter valued at about $146,000. Finally, RA Capital Management L.P. purchased a new stake in shares of Climb Bio during the 1st quarter worth about $38,332,000. 69.76% of the stock is owned by hedge funds and other institutional investors.
Climb Bio Company Profile
(
Get Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Recommended Stories
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
